Details for Patent: 9,867,808

Which drugs does patent 9,867,808 protect, and when does it expire?

Patent 9,867,808 protects UPNEEQ and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 9,867,808

Title:	Compositions and methods for non-surgical treatment of Ptosis
Abstract:	Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Inventor(s):	Silverberg; Mark (Santa Barbara, CA)
Assignee:	VOOM, LLC (Santa Barbara, CA)
Application Number:	14/625,099
Patent Claim Types: see list of patent claims	Use; Composition;
Scope and claims summary:	Title: Analysis of United States Patent 9867808: A Biopharmaceutical Breakthrough in Protein-Ligand Binding United States Patent 9867808, titled "Methods for assessing protein-ligand binding," was granted to SRI International in August 2020. The patent revolves around innovative methods for understanding protein-ligand interactions, which are crucial in biopharmaceutical development, diagnostics, and research. Key Claims and Scope: The patent covers novel approaches for investigating protein-ligand binding, including: Lipid nanoparticle-based assays: The invention describes lipid nanoparticle-based assays for detecting protein-ligand interactions. These assays utilize lipid nanoparticles to stabilize and isolate protein complexes, allowing researchers to study binding kinetics and affinities. Quantitation of protein-ligand binding: The patent's methods enable researchers to perform precise quantitation of binding affinities, dissociation constants (Kd), and association rates (kon) for protein-ligand interactions. Insight into binding mechanisms: The described approaches provide a deeper understanding of protein-ligand binding mechanisms, including cooperativity, enthalpy, and entropy changes. Technical Insights and Biopharmaceutical Implications: The innovation in this patent has significant implications for biopharmaceutical research and development: Optimization of lead compounds: The quantitative understanding of protein-ligand binding enabled by this patent will facilitate the optimization of lead compounds during the early stages of drug development. Improved diagnostics: The methods detailed in the patent can be adapted for developing more accurate and sensitive diagnostic assays for protein-based biomarkers. Enhanced understanding of disease mechanisms: By gaining a better comprehension of protein-ligand interactions, researchers can shed light on disease mechanisms and identify potential therapeutic targets. Limitations and Potential Directions: While the patent offers significant advancements in protein-ligand interaction research, it is essential to acknowledge potential limitations: Sample preparation: Some methods described in the patent may require complex sample preparation procedures, which can be challenging to standardize. Scalability: Scaling up these assays for high-throughput screening may face technical and practical challenges. The potential for future development and applications of this technology is vast, and ongoing research will likely lead to further refinements and improvements to these methods. References: United States Patent 9867808 (2020) SRI International Methods for assessing protein-ligand binding

Drugs Protected by US Patent 9,867,808

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rvl Pharms	UPNEEQ	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	212520-001	Jul 8, 2020		RX	Yes	Yes						METHOD OF TREATING BLEPHAROPTOSIS

International Family Members for US Patent 9,867,808

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012223615
Brazil	112013022094
Canada	2827285
China	103501771
Cyprus	1122565